Results of a US study of elderly men and women with a family history of Alzheimer's suggest that the nonsteroidal anti-inflammatory drugs (NSAIDs) naproxen and celecoxib did not improve cognitive function and the investigators recommended against using them to prevent Alzheimer's.
Previous research, based on observational studies, has suggested that risk of Alzheimer's is lower in people who use NSAIDs, supporting the idea that inflammatory processes are involved in the development of the neurodegenerative disease and in the decline of cognitive function such as thinking, memory and learning. The longitudinal study is the work of the ADAPT research group and was published in the online ahead of print issue of the Archives of Neurology on 12th May. The purpose was to investigate the effect of two NSAIDs, naproxen (brands include Aleve, Synflex, Naprelan) and celecoxib (brands include Celebrex and Celebra) on cognitive ability in the elderly.
ADAPT stands for the Alzheimer's Disease Anti-inflammatory Prevention Trial, a randomized, placebo-controlled, multicenter, primary prevention trial sponsored by the National Institute on Aging. The trial ran from March 2001 to December 2004 and recruited over 2,500 participants who were aged 70 and over, from areas surrounding the 6 trial sites: Baltimore, Maryland; Boston, Massachusetts; Rochester, New York; Seattle, Washington; Sun City, Arizona; and Tampa, Florida. The participants had to have a history of at least 1 first-degree relative with Alzheimer's-like dementia, and not have cognitive impairment at the time of recruitment (this was tested using a battery of cognitive tests). Anyone using NSAIDs regularly was excluded, but anyone using up to 81 mg a day of aspirin was included. 2,117 participants completed the trial and had follow up cognitive assessments. The participants were randomly assigned to three groups. One group, comprising around 600 participants, took Celecoxib (200 mg twice daily), a second group, also comprising about 600 of the participants took naproxen sodium (220 mg twice daily), and the third group, comprising around 900 of the participants, had the placebo.
The main outcome measures were seven tests of cognitive skills, and an overall summary score of all the tests, measured each year. The study finished early, in December 2004, because a previous study showed a link between celecoxib and increased risk of cardiovascular problems. The researchers said there could be several explanations for why these results clash with previous observational studies. Firstly, observational studies do not randomly assign patients to treatment groups and then monitor the effects of interventions; they follow and analyze the behaviour or symptoms of groups that are already formed, and additional factors that were not measured may have disturbed the results of such previous studies, suggested the authors. Secondly, the results of this trial may not apply to the NSAIDs such as ibuprofen, only to celecoxib and naproxen, and thirdly, perhaps NSAIDs only have protective powers when taken several years before cognitive function would start to fall.
They recommended continued follow up of participants after treatment, in order to find out if there are any further delayed timing effects. However, in the meantime they recommended that "naproxen and celecoxib should not be used for the prevention of Alzheimer's disease"..http://www.medicalnewstoday.com
posted by Valery Yermalitsky at
6:43 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home